2022 Symposium Videos
* Video for Dr. Umar Mahmood’s talk from 3:20pm-3:45pm will be released at a later time.
8:30am – 8:45am: Welcome
8:45am – 9:30am: The Future of Radiology & Integrated Diagnostics: Building on Sam Gambhir's Vision
9:30am – 9:55am: Early Diagnosis: Tales from the Esophagus
9:55am – 10:20am: Emerging CT Technology: Photon Counting CT
10:35am – 11:00am: Radiometals in Theranostics: From Chelate Chemistry to in vivo Studies
11:00am – 11:20am: Advances in Nuclear Medicine and Theranostics
11:20am – 11:50am: Trainee Programming
1:00pm – 1:25pm: Molecular Imaging: Imaging Integrins, Bench to Bedside
1:25pm – 1:50pm: Image-guidance for in vivo Cellular Control
1:50pm – 2:15pm: Genetic Factors in Breast Cancer Screening and Imaging
2:30pm – 2:55pm: Monitoring and Modulating the Electrophysiology of the Digestive System
2:55pm – 3:20pm: New Insights into the Bone-Fat Connection
3:45pm – 4:00pm: Closing Remarks
Agenda
July 18, 2022 | 8:30am - 4:00pm PT
8:30am - 8:45am
Welcome
Lloyd Minor, MD
Dean
Stanford University School of Medicine
Aruna Gambhir, MS, MBA
CEO
CellSight Technologies
Joseph Wu, MD, PhD
Director, Stanford CVI and Professor of Medicine and Radiology
Stanford University
8:45am - 9:30am
Keynote: The Future of Radiology and Integrated Diagnostics: Building on Sam Gambhir's Vision
Garry Gold, MD
Professor and Chair
Stanford Radiology
Moderator
Joseph Wu, MD, PhD
Director, Stanford CVI and Professor of Medicine and Radiology
Stanford University
9:30am - 9:55am
Early Diagnosis: Tales from the Esophagus
Rebecca Fitzgerald, MD, FMedSci
Professor
University of Cambridge
Moderator
Viswam Nair, MD, MS
Associate Professor
Clinical Research Division, Fred Hutchinson Cancer Center
9:55am - 10:20am
Emerging CT Technology: Photon Counting CT
David Bluemke, MD, PhD
Professor
University of Wisconsin Madison
Moderator
Natesh Parashurama, MD, PhD
Assistant Professor
University of Buffalo, State University of NY
10:20am - 10:35am
Break
10:35am - 11:00am
Radiometals in Theranostics: From Chelate Chemistry to
in vivo Studies
Carolyn Anderson, PhD
Professor
University of Missouri
Moderator
Jason Lee, PhD
Deputy Director, Molecular Imaging Program
Stanford Radiology
11:00am - 11:20am
Advances in Nuclear Medicine and Theranostics
Johannes Czernin, MD
Professor of Molecular and Medical Pharmacology
UCLA
Moderator
Jason Lee, PhD
Deputy Director, Molecular Imaging Program at Stanford
Stanford Radiology
11:20am - 11:50am
Trainee Programming
Parag Mallick, PhD
Associate Professor
Stanford Radiology
Edward Graves, PhD
Associate Professor
Radiation Oncology
Stanford University
Moderators
Bryan Smith, PhD
Associate Professor
Michigan State University
Natesh Parashurama, MD, PhD
Assistant Professor
University of Buffalo, State University of NY
11:50am - 1:00pm
Lunch
1:00pm - 1:25pm
Molecular Imaging: Imaging Integrins, Bench to Bedside
Julie Sutcliffe, PhD
Professor of Biomedical Engineering and Hematology and Oncology
University of California Davis
Moderator
Bryan Smith, PhD
Associate Professor
Michigan State University
1:25pm - 1:50pm
Image-guidance for in vivo Cellular Control
Christopher Contag, PhD
Professor and Director
Institute for Quantitative Health Science and Engineering
Michigan State University
Moderator
Ryan Spitler, PhD
Deputy Director, PHIND and Canary Centers
Stanford Radiology
1:50pm - 2:15pm
Genetic Factors in Breast Cancer Screening and Imaging
Bruce Haffty, MD
Professor and Chairman
Rutgers Cancer Institute of New Jersey
Moderator
Ramasamy Paulmurugan, PhD
Professor
Stanford Radiology
2:15pm - 2:30pm
Break
2:30pm - 2:55pm
Monitoring and Modulating the Electrophysiology of the Digestive System
Todd Coleman, PhD
Associate Professor of Bioengineering
Stanford University
Moderator
Bryan Smith, PhD
Associate Professor
Michigan State University
2:55pm - 3:20pm
New Insights into the Bone-Fat Connection
Miriam Bredella, MD, MBA
Professor and Vice Chair of Radiology
Harvard Medical School and Massachusetts General Hospital
Moderators
Natesh Parashurama, MD, PhD
Assistant Professor
University of Buffalo, State University of NY
3:20pm - 3:45pm
Cancer Immunotherapy Imaging
Umar Mahmood, MD, PhD
Professor of Radiology
Massachusetts General Hospital
Moderators
Israt Alam, PhD
Senior Scientist
Stanford Radiology
3:45pm - 4:00pm
Closing Remarks
Garry Gold, MD
Professor and Chair
Stanford Radiology
Speakers
Carolyn Anderson, PhD
Professor
University of Missouri
Bio
Carolyn Anderson is the Simón-Ellebracht Professor of Medicinal Chemistry and Professor of Radiology at the University of Missouri. Her lab performs the design, synthesis, and biological evaluation of novel radiometal-based radiopharmaceuticals for diagnostic imaging and targeted radiotherapy of cancer and other diseases. A current focus of her research lab is the development of imaging agents for up-regulated receptors on immune cells that are involved in inflammation related primary tumor growth and cancer metastasis, and sickle cell disease.
David Bluemke, MD, PhD
Professor
University of Wisconsin Madison
Bio
Dr. David Bluemke is Professor of Radiology at the University of Wisconsin School of Medicine and Public Health. Dr. Bluemke is the Editor of the journal Radiology, the field’s most prominent scholarly journal. He was previously the Director of Radiology and tenured investigator at the NIH in Bethesda, Maryland and Professor of Radiology and Medicine at the Johns Hopkins University School of Medicine. Dr. Bluemke’s research has focused on early detection and diagnosis of cardiovascular disease using noninvasive imaging techniques, particularly MRI and CT. He is an author of more than 770 peer reviewed papers, and more than 30 books and book chapters.
Miriam Bredella, MD, MBA
Professor and Vice Chair of Radiology
Harvard Medical School and Massachusetts General Hospital
Bio
Dr. Bredella is Professor of Radiology at Harvard Medical School, Vice Chair for Faculty Affairs and Clinical Operations in the Department of Radiology at the Massachusetts General Hospital (MGH), and the Director of the MGH-wide Center for Faculty Development.
Dr. Bredella is PI of the NIH-funded Harvard KL2/Catalyst Medical Research Investigator Training Program where she mentors clinical translational researchers across all Harvard hospitals and specialties. She has been elected to be a member of the NIH Clinical and Translational Science Awards (CTSA) Program Steering Committee and chairs several CTSA working groups. She is an active member of the Diversity and Inclusion Task Forces at MGH and Harvard Medical School where she designed successful initiatives for increasing diversity in research operations.
Dr. Bredella’s research focuses on the effects of different fat depots on bone metabolism and metabolic risk in states of under- and overnutrition. She established a multidisciplinary clinical research program in the area of metabolic imaging that combines innovative translational, clinical, and outcomes research. She is the recipient of multiple awards, including the Distinguished Investigator Award from the Academy of Radiology Research, the Presidents Medal of the International Skeletal Society, the Innovative Initiatives Award from the Boston Women’s Workforce Council and the Shirley Driscoll Dean’s Leadership Award for the Enhancement of Women’s Careers from Harvard Medical School.
Todd Coleman, PhD
Associate Professor of Bioengineering
Stanford University
Bio
Todd P. Coleman received B.S. degrees in electrical engineering (summa cum laude), as well as computer engineering (summa cum laude) from the University of Michigan. He received M.S. and Ph.D. degrees from MIT in electrical engineering and did postdoctoral studies at MIT in neuroscience. He is currently the Yu Family Faculty Scholar in the School of Engineering and an Associate Professor in the Department of Bioengineering at Stanford University. Dr. Coleman’s research is very multi-disciplinary, using tools from applied probability, physiology, and bioelectronics. His research spans from developing fundamental information theory and machine learning techniques to developing technologies to monitor and modulate physiology of the nervous systems in the brain and visceral organs. He has been selected as a National Academy of Engineering Gilbreth Lecturer, as a Fellow of IEEE, and a Fellow as the American Institute for Medical and Biological Engineering. He is currently the Chair of the National Academies Standing Committee on Biotechnology Capabilities and National Security Needs.
Christopher Contag, PhD
Professor and Director
Institute for Quantitative Health Science and Engineering Michigan State University
Bio
Dr. Contag joined Michigan State University in 2017 as the founding director of the Institute for Quantitative Health Science and Engineering (IQ) and the inaugural chair of the Department of Biomedical Engineering; he is a professor of Microbiology and Molecular Genetics, and Biomedical Engineering. Dr. Contag received his B.S. in Biology, and his Ph.D. in Microbiology from the University of Minnesota. He was a postdoctoral fellow at Stanford University from 1990-1994 in Microbiology, and then joined the faculty in Pediatrics at Stanford in 1995. At Stanford, Dr. Contag served as the Associate Chief of the Division of Neonatal and Developmental Medicine, the director of Stanford’s Center for Innovation in In Vivo Imaging (SCI3) and co-director of both the Molecular Imaging Program at Stanford (MIPS) and Child Health Research Institute (CHRI); Dr. Contag is professor emeritus at Stanford University. He founded the Companies Xenogen, PixelGear, BioEclipse, and EXOForce.
Johannes Czernin, MD
Professor of Molecular and Medical Pharmacology
University of California Los Angeles
Bio
Dr. Johannes Czernin is a Professor of Molecular and Medical Pharmacology at the David Geffen School of Medicine at UCLA. He received his MD degree from the University of Vienna in 1983 and was board certified in Internal Medicine in Austria in 1989 and in Nuclear Medicine in 1996 in the USA. He was named Director of Nuclear Medicine at the David Geffen School of Medicine at UCLA in 1996 and currently serves as the Chief of the Ahmanson Translational Theranostics Division at UCLA. The Division includes the Nuclear Medicine Clinic, a clinical imaging research program, a drug and probe development program with a strong underpinning in tumor biology, a preclinical imaging and biomedical radiochemistry center. His group successfully applied to the FDA for an NDA for a PSMA targeted PET imaging probe in prostate cancer. The Division collaborates within the department of molecular and medical pharmacology and across several other departments including urology, radiation oncology, oncology, surgery, radiology, neurology, pathology and others to advance preclinical and clinical theranostics. Dr. Czernin is currently Editor-in-Chief of the Journal of Nuclear Medicine and is a past president of the Academy of Molecular Imaging. He has published more than 290 peer-reviewed research papers.
Rebecca Fitzgerald, MD, FMedSci
Professor
University of Cambridge
Bio
Rebecca Fitzgerald is Professor of Cancer Prevention at the University of Cambridge and is a practising cancer consultant in Britain’s National Health Service. She is a specialist in cancer of the oesophagus, and has won multiple prestigious awards including the Westminster Medal, Jane Wardle and Don Listwin prizes for developing a new diagnostic method known as ‘Cytosponge-TFF3’ from conception through to clinical implementation. She has been elected a Fellow of the (British) Academy of Medical Sciences and as a member of EMBO. Rebecca jointly chaired the recent Evidence Review Report on cancer screening in Europe that was conducted by the Federation of European Academies of Medicine to inform the work of the Group of Chief Scientific Advisors to the European Commission.
Aruna Gambhir, MS, MBA
CEO
CellSight Technologies
Bio
Aruna Gambhir is an entrepreneur with over 28 years of experience in sales, marketing, engineering, and operations. She has a BS in Biochemistry from University of California Berkeley, MS in Computer Science from Santa Clara University, and an MBA from University of California Los Angeles. She started her career in biotech at the University of California San Francisco then made a detour into high tech and worked at several Silicon Valley start-ups; initially in engineering then transitioned to marketing. After the multimedia tools start-up, Gain Technology, was acquired by Sybase she joined Siebel Systems as an early employee and helped oversee growth of sales consulting and operations worldwide. Siebel went public and reached sales revenue of $1 billion+ per year with over 3000 employees. Post IPO she “retired”, joined the boards of multiple non-profit foundations and advocacy groups, and was Executive Director at the Siebel Foundation and Marketing Director at the Canary Foundation. Aruna resumed her entrepreneurial drive to lead CellSight from initial technology transfer to clinical trials.
Garry Gold, MD
Professor and Chair of Radiology
Stanford University
Bio
Garry Gold, M.D., Professor of Radiology and (by courtesy) Bioengineering and Orthopedics, has been dedicated to using MRI to improve imaging of musculoskeletal conditions for over 25 years, and has made numerous important contributions, including the first application of ultra-short echo time imaging to musculoskeletal disorders. His research program is known for innovation in MRI of osteoarthritis, and his research focuses on the application of advanced MRI techniques to joint disease, specifically using imaging to better understand the mechanism and progression of osteoarthritis, and he has received numerous awards, patents, and extensive grant funding for this work throughout his career. He has collaborated with students, residents and young investigators throughout his career, resulting in more than 200 articles published in peer-reviewed journals, and over 400 presentations at national and international meetings.
Bruce Haffty, MD
Professor and Chairman
Rutgers Cancer Institute of New Jersey
Bio
Bruce G. Haffty, M.D., FACR, FASTRO, is Associate Vice Chancellor, Cancer Programs, Rutgers Biomedical Health Sciences, Rutgers Cancer Institute of New Jersey, Professor and Chairman of Radiation Oncology, Rutgers-Robert Wood Johnson Medical School, New Jersey Medical School. His medical school, internship and residency training was at Yale School of Medicine. He spent the majority of his academic career at Yale, where he was Professor of Therapeutic Radiology, residency program director from 1992 through 2004, Vice Chairman and Clinical Director from 2002-2005. He moved to Rutgers Cancer Institute of New Jersey in 2005.
Dr. Haffty has a long and successful record in clinical and translational research in radiation oncology. He has focused his efforts on molecular/genetic factors as they relate to radiation resistance and outcomes in patients undergoing radiation. Dr. Haffty is also a leader in national clinical trials. He has coauthored a number of national clinical trials papers in high impact journals. He is currently co-investigator on several national clinical trials through the NRG and Alliance cooperative groups. He has published over 400 peer-reviewed articles, 30 book chapters, and numerous editorials and letters. He is consistently listed as one of the country’s leading physicians and best doctors through national registries.
In addition to a busy clinical practice, Dr. Haffty has served on numerous national committees related to research and education in breast cancer and radiation oncology. He is a Past President of the American Radium Society, past Chairman of the Residency Review Committee in Radiation Oncology, past President of the American Board of Radiology, and past President and Past Chairman of the Board of ASTRO. He is the 2020 recipient of ASTRO’s Gold Medal. He currently serves as Deputy Editor of the Journal of Clinical Oncology and is currently President-Elect of RSNA.
Umar Mahmood, MD, PhD
Professor of Radiology, Chief of Nuclear Medicine and Molecular Imaging
Massachusetts General Hospital / Harvard Medical School
Bio
Dr. Umar Mahmood is Chief of Nuclear Medicine and Molecular Imaging, Director of the Center for Precision Imaging, and Associate Chair for Imaging Sciences in the Department of Radiology at Massachusetts General Hospital, and Professor of Radiology at Harvard Medical School.
Dr. Mahmood’s research has focused on translational applications of molecular imaging to guide precision medicine, with an emphasis on the tumor microenvironment, cancer signaling pathways, changes in cancer metabolism, and the interaction of the immune system with tumors. He is interested in applying image information for disease characterization and optimization of individual treatment response. In addition to his work at MGH, he serves on the Board of Directors the Radiological Society of North America (RSNA) and Board of Trustees of the RSNA Research and Education Foundation. He recently completed terms on the Board of Directors of the Society of Nuclear Medicine and Molecular Imaging (SNMMI), and as Chair of the Board of Scientific Counselors of the NIH Clinical Center.
Lloyd Minor, MD
Dean, School of Medicine
Stanford University
Bio
Lloyd B. Minor, MD, is the Carl and Elizabeth Naumann Dean of the Stanford University School of Medicine. With his leadership, Stanford Medicine has established a strategic vision to lead the biomedical revolution in Precision Health, a fundamental shift to more proactive and personalized health care that empowers people to lead healthy lives. His book, “Discovering Precision Health,” published in 2020, highlights how biomedical advances are dramatically improving our ability to treat and cure complex diseases. Dr. Minor also is a professor of Otolaryngology–Head and Neck Surgery and a professor of Bioengineering and of Neurobiology, by courtesy, at Stanford University. With more than 160 published articles and chapters, Dr. Minor is an expert in balance and inner ear disorders. In 2012, he was elected to the National Academy of Medicine.
Julie Sutcliffe, PhD
Professor
University of California Davis
Bio
Dr. Sutcliffe is a Professor of Internal Medicine and Biomedical Engineering at the University of California Davis. She serves as the co-director of the Center for Molecular and Genomic imaging and as the director of radiochemistry. Dr Sutcliffe is the leader of a multidisciplinary translational research team that is recognized nationally for it contributions to the field of Molecular Imaging. Dr Sutcliffe is the Principal investigator of 3 active clinical trials, she is the Principal investigator of the UC Davis U01 Pancreatic Cancer Detection Consortium and is the leader of the UC Davis Lustgarten Foundation/ StandupToCancer Pancreatic Cancer Collective Research Team. She is a Fellow of the Society of Nuclear Medicine and Molecular Imaging, a Fellow of the World Molecular Imaging Society and Fellow of the American Institute for Medical and Biological Engineering. She is the co-president of the World Molecular Imaging Society.
Joseph Wu, MD, PhD
Director, Stanford Cardiovascular Institute and Simon H. Stertzer, MD Professor of Medicine and Radiology
Stanford University
Bio
Joseph C. Wu, MD, PhD is Director of the Stanford Cardiovascular Institute (http://cvi.stanford.edu/) and the Simon H. Stertzer, MD, Professor of Medicine and Radiology. Dr. Wu received his medical degree from Yale. He completed his medicine internship, residency and cardiology fellowship training at UCLA followed by a PhD (Molecular & Medical Pharmacology) in the UCLA STAR program. His clinical interests involve adult congenital heart disease and cardiovascular imaging.
His lab works on biological mechanisms of patient-specific and disease-specific induced pluripotent stem cells (iPSCs). The main goals are to (i) understand mechanisms of cardiovascular diseases, (ii) accelerate drug discovery, (iii) develop “clinical trial in a dish” concept, and (iv) implement precision medicine for cardiovascular patients. His lab uses a combination of stem cells, genomics, epigenetics, cellular & molecular biology, physiological testing, and molecular imaging technologies. Dr. Wu has published >450 manuscripts with H-index of 113 on Google scholar. He is listed as top 1% highly cited researchers in Web of Science (2018, 2019, 2020, 2021). Among his trainees, >40 of them are principal investigators in the US or abroad (http://med.stanford.edu/wulab.html).
Dr. Wu has received numerous awards, including the National Institutes of Health (NIH) Director’s New Innovator Award, NIH Roadmap Transformative Award, American Heart Association (AHA) Innovative Research Award, Presidential Early Career Award for Scientists and Engineers (PECASE) given by President Obama, Burroughs Wellcome Foundation Innovation in Regulatory Science Award, and American Heart Association Distinguished Scientist Award. Dr. Wu serves on the FDA Cellular Tissue and Gene Therapies Advisory Committee. Dr. is on the Board of Directors for Keystone Symposia and is President-Elect of the American Heart Association.
Dr. Wu is an elected member of American Society of Clinical Investigators (ASCI), Association of University Cardiologists (AUC), American Institute for Medical and Biological Engineering (AIMBE), American Association of Physicians (AAP), American Association for the Advancement of Science (AAAS), and National Academy of Medicine (NAM).